Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(2000): Ernst E+, Forsch Komplementarmed Klass Naturheilkd
7(1), 17
(2000): Thomson KF+, Br J Dermatol 142, 84
(2000): Varma S+, Contact Dermatitis 42(5), 309
(1997): Hackzell-Bradley M+, Lakartidningen 94(47), 4359
(1994): Selvaag E+, Contact Dermatitis 31(2), 124
(1993): de Groot AC+, Contact Dermatitis 28(5), 309
Burning
(2002): Groppo FC+, IntDentJ52(6), 433
Dermatitis
(2005): Hartford O+, Cutis 76(3), 178
(2005): Willcox M, Nurs Times 101(11), 32
(2003): Perrett CM+, Clin Exp Dermatol 28(2), 167
(2002): Schempp CM+, Hautarzt 53(2), 93
(2001): Fritz TM+, Ann Dermatol Venereol 128(2), 123 (7 cases)
(2000): Khanna M+, Am J Contact Dermat 11(4), 238
(1999): Bruynzeel DP, Trop Med Int Health 4(9), 630
(1999): Greig JE+, Contact Dermatitis 41(6), 354
(1999): Hausen BM+, Am J Contact Dermat 10(2), 68
(1998): Rubel DM+, Australas J Dermatol 39(4), 244
(1998): Wolner-Hanssen P+, Lakartidningen 95(30), 3309
(1997): Bhushan M+, Contact Dermatitis 36(2), 117
(1997): Kranke B, Hautarzt 48(3), 203
(1996): De Groot AC, Contact Dermatitis 35(5), 304
(1994): Knight TE+, JAmAcadDermatol30(3), 423
(1994): van der Valk PG+, Ned Tijdschr Geneeskd 138(16), 823
(4 cases)
(1992): de Groot AC+, Contact Dermatitis 27(4), 279
(1991): Apted JH, Australas J Dermatol 32(3), 177
Eczema
(2002): Dharmagunawardena B+, Contact Dermatitis 47(5), 288
Erythema multiforme
(2000): Khanna M+, Am J Contact Dermat 11(4), 238
Inflammation
(1999): Syed TA+, Trop Med Int Health 4(4), 284 (4 cases) (with
butenafine)
Linear IgA dermatosis
(2003): Perrett CM+, Clin Exp Dermatol 28(2), 167
Pruritus
(1998): Wolner-Hanssen P+, Lakartidningen 95(30), 3309
Rash (sic)
Sensitization
(1999): Hausen BM+, Am J Contact Dermat 10(2), 68
Toxicity (sic)
(1995): Carson CF+, J Toxicol Clin Toxicol 33(2), 193
Other
Gynecomastia
(2007): Dean CJ, NEnglJMed356(24), 2543
(2007): Henley DV+, NEnglJMed356(5), 479
(2007): Kalyan S, NEnglJMed356(24), 2542
Hypersensitivity
(2003): Mozelsio NB+, Allergy Asthma Proc 24(1), 73
(2001): Fritz TM+, Ann Dermatol Venereol 128(2), 123 (7 cases)
Side effects (sic)
(2000): Ernst E, Br J Dermatol 143(5), 923
Note: Tea tree oil in bottles may undergo photooxidation, and
degradation products are moderate to strong sensitizers.
The plant was discovered and named by Captain James Cook of the
Royal Navy in 1770, who found groves of trees with sticky, aromatic
leaves that, when boiled, made a spicy tea
TEGASEROD
Trade name: Zelnorm (Novartis)
Indications: Irritable bowel syndrome
Category: 5-HT4 agonist; Serotonin type 4 receptor agonist
Half-life: 11±5 hours
Clinically important, potentially hazardous interactions
with: None
Reactions
Skin
Diaphoresis
Facial edema
Pruritus
Raynaud’s phenomenon
(2003): Bertoli R+, Eur J Clin Pharmacol 58(10), 717
Mucosal
Oral vesiculation
Other
Abdominal pain
(2007): Kale-Pradhan PB+, Pharmacotherapy 27(2), 267
(2006): Muller-Lissner S+, Am J Gastroenterol 101(11), 2558 (%)
(2004): Schoenfeld P, Aliment Pharmacol Ther 20, 25
(2002): Fidelholtz J+, Am J Gastroenterol 97(5), 1176
(2002): Tougas G+, Aliment Pharmacol Ther 16(10), 1701 (7%)
Pain
TELBIVUDINE
Trade name: Tyzeka (Novartis)
Indications: Hepatitis B (chronic)
Category: Nucleoside analog reverse transcriptase inhibitor
Half-life: ~15 hours
Clinically important, potentially hazardous interactions
with: N/A
Reactions
Skin
Rash (sic) (4%)
Other
Abdominal pain (12%)
Cough (7%)
Fever (4%)
Myalgia/Myositis/Myopathy/Myotoxicity (3%)
Upper respiratory infection (>5%)
TELITHROMYCIN
TELITHROMYCIN 523
Synonyms: HMR 3647; RU-647; RU-66647
Trade name: Ketek (Sanofi-Aventis)
Indications: Community-acquired pneumonia, chronic bronchitis
Category: Antibiotic, macrolide
Half-life: 10–13 hours
Clinically important, potentially hazardous interactions
with: atorvastatin, carbamazepine, cisapride, cyclosporine,
digoxin, dihydroergotamine, ergotamine, hexobarbital, lapatinib,
lovastatin, metoprolol, midazolam, phenobarbital, phenytoin,
pimozide, rifampin, rimonabant, simvastatin, sirolimus,
tacrolimus, temsirolimus, triazolam, warfarin